byiShook Opinion
Feb 6, 2025 - 08:45
Eli Lilly earnings topped Q4 views with 2025 guidance above consensus, even though Zepbound and Mounjaro slightly missed. Eli Lilly stock rose. The post Eli Lilly Earnings Top, 2025 Guidance Strong, But Weight-Loss Drug Sales Miss appeared first on Investor's Business Daily.
Eli Lilly earnings topped Q4 views with 2025 guidance above consensus, even though Zepbound and Mounjaro slightly missed. Eli Lilly stock rose.
The post Eli Lilly Earnings Top, 2025 Guidance Strong, But Weight-Loss Drug Sales Miss appeared first on Investor's Business Daily.